Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR)

Liraglutide, a glucagon-like peptide 1 (GLP1) receptor agonist, is known to inhibit the atherosclerosis of apoE mice and suppress the cellular behaviors of VSMCs induced by AngII. This study aimed to explore whether liraglutide can reduce the proliferation, invasion and phenotypic transformation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Jingquan, Feng, Ming, Niu, Xiaohong, Zhang, Xinyu, Wang, Yilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806487/
https://www.ncbi.nlm.nih.gov/pubmed/34666623
http://dx.doi.org/10.1080/21655979.2021.1982304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806487/
https://www.ncbi.nlm.nih.gov/pubmed/34666623
http://dx.doi.org/10.1080/21655979.2021.1982304

Ejemplares similares